Hormone combo could boost diabetes control in menopause

NCT ID NCT06715514

Ongoing Disease control Sponsor: Lia Bally Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This study looks at whether adding menopausal hormone therapy to a GLP-1 drug (semaglutide) improves blood sugar control in early postmenopausal women who have or are at risk for type 2 diabetes. About 96 women with menopausal symptoms and a BMI of 27 or higher will be enrolled. The main goal is to see if the combination works better than the GLP-1 drug alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (Wegovy) and menopausal hormone therapy (estradiol and micronized progesterone)
What this could lead to: If it works, this could point toward a more effective treatment for preventing or managing type 2 diabetes in early postmenopausal women.
What could go wrong: This is a small, early-phase study with only 96 participants, so results may not apply to everyone. The combination therapy may also have side effects like nausea or hormone-related risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENOPAUSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENOPAUSE TYPE 2 DIABETES

Contacts and locations

Locations

University Hospital Bern

Bern, 3010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.